



# Risk factors and salient features of Acute Kidney Injury in Diabetic Ketoacidosis



Soumik Goswami<sup>1\*</sup>, Deep Hathi<sup>2</sup>, Atma Prakash Nayak<sup>3</sup> and Manish Jain<sup>4</sup>

<sup>1</sup>Assistant Professor, Endocrinology, Nilratan Sircar Medical College, India

<sup>2</sup>Senior Resident, Endocrinology, Nilratan Sircar Medical College, India

<sup>3</sup>Senior Resident, Nephrology, Apollo Gleneagles Hospital, India

<sup>4</sup>Consultant Nephrologist, Apollo Gleneagles Hospital, India

Submission: November 03, 2022; Published: November 17, 2022

\*Corresponding author: Soumik Goswami, Asst. Professor of Endocrinology and Senior Resident Nephrology, Sircar Medical College, India

## Abstract

Diabetic ketoacidosis (DKA) is a life-threatening complication of diabetes mellitus (DM). The morbidity, mortality and long-term renal outcomes in DKA are influenced by the occurrence of acute kidney injury (AKI). However, AKI in DKA remains undiagnosed and the incidence and severity of AKI in DKA is still unknown. This review article focusses on the risk factors and salient features of acute kidney injury in diabetic ketoacidosis. Peer reviewed articles from 1995 to 2021 were accessed from PubMed and reviewed.

## Introduction

Diabetic ketoacidosis (DKA) is one of the leading causes of hospitalization, morbidity and mortality in diabetic patients [1-4]. DKA manifests with hyperglycaemia, metabolic acidosis, ketosis, volume loss, and electrolyte abnormalities along with AKI. AKI in DKA is known to lead to worsening of short- and long-term outcomes but has not been systematically studied. Brenden E et al. found that 44 of 106 (41.5%) DKA patients with AKI did not have documentation of AKI resolution prior to discharge [5]. AKI remained undiagnosed in the absence of universal diagnostic criterion but using the RIFLE classification [6], the incidence and severity of AKI among different populations and settings can now be compared [7]. We conducted a PubMed search including articles published from 1995 to 2021 with the MeSH terms “acute kidney injury”, “acute renal failure” and “diabetic ketoacidosis”

## Risk Factors for Developing Acute Kidney Injury in Diabetic Ketoacidosis

AKI was more common in elderly patients. Tachycardia, coma, severity of acidosis and proteinuria were independently associated with increased incidence of AKI in DKA patients. Movement of fluid from the intracellular to extracellular compartment due to insulin deficiency and renal hypoperfusion leads to development of AKI in DKA. AKI in DKA is often volume responsive. Almost

50% of AKI patients had recovery of renal function in less than 24 hours [8,9].

Junzhe Chen et al. found that the AKI group was older and had a higher incidence of cardiovascular disease (CVD) and chronic kidney disease (CKD) than the non-AKI group ( $P < 0.05$ ). Tachycardia, coma on admission and proteinuria were documented more in the AKI group compared to the non-AKI group ( $P < 0.05$ ). AKI patients had higher blood glucose, serum uric acid and total leukocyte count (TLC) and lower pH and serum albumin levels compared to the non-AKI patients ( $P < 0.05$ ) [1].

Using multivariate logistic regression, Junzhe Chen et al identified older age [odds ratio-OR (95% confidence interval-CI) 1.033 (1.009–1.058),  $P = 0.008$ ]; increased glucose [OR (95%CI) 1.087 (1.034–1.142),  $P = 0.001$ ], serum uric acid [OR (95%CI) 1.006 (1.002–1.009),  $P = 0.001$ ], and TLC [OR (95%CI) 1.089 (1.026–1.157),  $P = 0.005$ ]; and decreased pH [OR (95%CI) 0.001 (0.000–0.080),  $P = 0.002$ ], and serum albumin [OR (95%CI) 0.937 (0.881–0.996),  $P = 0.038$ ]; along with coma at the time of admission [OR (95%CI) 12.389 (1.823–84.185),  $P = 0.010$ ] and pre-existing CKD [OR (95%CI) 6.250 (1.461–26.732),  $P = 0.013$ ] as risk factors for development of AKI in DKA patients [1]. Jean-Christophe Orban et al. found age, blood glucose and serum protein level as risk factors for developing AKI in DKA [2].

### Risk Factors for Long-Term Mortality in Dka Patients

The AKI group had significantly lower survival rate than the non-AKI group. Severity of AKI was associated with increased long-term mortality in DKA patients. Incidence of AKI, severity of AKI, need for renal replacement therapy and pre-existing chronic kidney disease were associated with progression of renal disease in DKA patients.

Junzhe Chen et al used Cox proportional hazards model to identify risk factors associated with long-term renal outcomes and mortality. In the study by Junzhe Chen et al, Kaplan-Meier analysis and the log-rank test were used to compare long-term renal outcomes and mortality between different AKI stages according to the KDIGO criteria. Cox proportional hazards modelling demonstrated that age ( $P=0.001$ ) and AKI ( $P=0.036$ ) were significantly associated with long-term mortality in DKA patients. The AKI group had lower survival rate than the non-AKI group [1]. The study by Giacomo Zoppini et al. [10] showed that eGFR decline in the DKA patients in the AKI group was  $6.4 \pm 5.0$  ml/min/1.73m<sup>2</sup> per year, while that in the DKA patients in the non-AKI group was  $1.9 \pm 3.8$  ml/min/1.73m<sup>2</sup> per year during the average follow-up period of 22 months ( $P < 0.01$ ). The decrease in eGFR in AKI group was 10.5 ml/min/1.73m<sup>2</sup> in the first 6 months to 1 year, whereas the decrease in the eGFR in the non-AKI group was 4.11 ml/min/1.73m<sup>2</sup> ( $P=0.001$ ). The deterioration of renal function slowed after 1 year but was significantly different between the AKI and non-AKI groups.

AKI is a key risk factor for progressive CKD and advanced stages of AKI are associated with higher risk of progressive CKD. Possible mechanisms involved in AKI transition to CKD include mitochondrial dysfunction, persistent chronic inflammation, oxidative stress endothelial dysfunction and microvascular rarefaction, inadequate regeneration of tubular cells, cell cycle arrest, response to DNA damage [11,12]. Many studies have demonstrated that diabetes is an independent risk factor for AKI and diabetic patients with AKI have significantly higher risk of progressing to CKD [13,14]. Diabetes is associated with reactive oxygen species (ROS) overproduction, mitochondrial dysfunction, inflammation and hypoxia [13]. Endothelial cell injury including abnormal function and apoptosis and a decrease in peritubular capillaries is associated with the reduced expression of VEGF-A which can be induced by hyperglycaemia [15,16]. Mitochondrial damage has been noted in podocytes treated with high glucose and experimental or clinical diabetic kidney disease [17,18]. In a pathological state, the tubular system can set up and maintain the cycle for inflammation, hypoxia and apoptosis [19]. *In vivo* and *in vitro* studies have demonstrated that hyperglycaemia can induce proximal tubular cells to secrete extracellular matrix through the TGF- $\beta$ -dependent pathway which is the main mechanism of AKI to CKD progression [20,21]. The increase in proinflammatory cytokines, oxidative stress and raised levels of ketones can increase the expression of adhesion molecules in endothelial

cells and cause monocytes to adhere, resulting in tissue damage [22-23]. The above-mentioned mechanisms may explain how AKI affects the long-term renal outcome of DKA.

### Conclusion

Diabetic ketoacidosis with AKI is not uncommon. Tachycardia, coma, severity of acidosis and proteinuria were associated with increased incidence of AKI in DKA patients. AKI patients had higher blood glucose, serum uric acid and TLCs and lower pH and serum albumin levels than non-AKI patients. Severity of AKI was associated with increased long-term mortality in DKA patients. Incidence of AKI, severity of AKI, need for renal replacement therapy and pre-existing chronic kidney disease are associated with progression of renal disease in DKA patients. Recognising and prevention of AKI in DKA patients is crucial in determining both short term and long-term renal outcomes.

### References

- Chen J, Zeng H, Ouyang X, Mingsheng Z, Qiuyan H, et al. (2020) The incidence, risk factors, and long-term outcomes of acute kidney injury in hospitalized diabetic ketoacidosis patients. *BMC Nephrol* 21(1): 48.
- Orban JC, Maiziere EM, Ghaddab A, Van Obberghen E, Ichai C (2014) Incidence and characteristics of acute kidney injury in severe diabetic ketoacidosis. *PLoS one* 9(10): e110925.
- Abdulrahman GO, Amphlett B, Okosieme OE (2013) Trends in hospital admissions with diabetic ketoacidosis in Wales, 1999–2010. *Diab Res Clin Pract* 100(1): e7–10.
- Lombardo F, Maggini M, Gruden G, Bruno G (2013) Temporal Trend in Hospitalizations for Acute Diabetic Complications: A Nationwide Study, Italy, 2001–2010. *PLoS one* 8(5): e63675.
- Hursh BE, Ronsley R, Islam N, Mammen C, Panagiotopoulos C (2017) Acute kidney injury in children with type 1 diabetes hospitalized for diabetic ketoacidosis. *JAMA Pediatr* 171(5): e170020.
- Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, et al. (2004) Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. *Crit Care* 8(4): R204–212.
- Woodrow G, Brownjohn AM, Turney JH (1994) Acute renal failure in patients with type 1 diabetes mellitus. *Postgrad Med J* 70(821): 192–194.
- Uchino S, Bellomo R, Bagshaw SM, Goldsmith D (2010) Transient azotaemia is associated with a high risk of death in hospitalized patients. *Nephrol Dial Transplant* 25(6): 1833–1839.
- Himmelfarb J, Joannidis M, Molitoris B, Schietz M, Okusa MD, et al. (2008) Evaluation and Initial Management of Acute Kidney Injury. *Clin J Am Soc Nephrol* 3(4): 962–967.
- Zoppini G, Targher G, Chonchol M, Ortalda V, Negri C, et al. (2012) Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function. *Clin J Am Soc Nephrol* 7(3): 401–408.
- Fiorentino M, Grandaliano G, Gesualdo L, Castellano G (2018) Acute kidney injury to chronic kidney disease transition. *Contrib Nephrol* 193: 45–54.
- Basile DP, Bonventre JV, Mehta R, Nangaku M, Unwin R et al. (2016) Progression after AKI: understanding maladaptive repair processes to predict and identify therapeutic treatments. *J Am Soc Nephrol* 27(3): 687–697.

13. Yu SMW, Bonventre JV (2018) Acute kidney injury and progression of diabetic kidney disease. *Adv Chronic Kidney Dis* 25(2): 166–180.
14. Thakar CV, Christianson A, Himmelfarb J, Leonard AC (2011) Acute kidney injury episodes and chronic kidney disease risk in diabetes mellitus. *Clin J Am Soc Nephrol* 6(11): 2567–2572.
15. Ho FM, Lin WW, Chen BC, Chao CM, Yang CR et al. (2006) High glucose-induced apoptosis in human vascular endothelial cells is mediated through NF- $\kappa$ B and c-Jun NH2-terminal kinase pathway and prevented by PI3K/Akt/eNOS pathway. *Cell Signal* 18(3): 391–399.
16. Lindenmeyer MT, Kretzler M, Boucherot A, Berra S, Yasuda Y et al. (2007) Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy. *J Am Soc Nephrol* 18(6): 1765–1776.
17. Feng J, Ma YQ, Chen ZW, Hu JJ, Yang Q et al. (2019) Mitochondrial pyruvate carrier 2 mediates mitochondrial dysfunction and apoptosis in high glucose-treated podocytes. *Life science* 237: 116941.
18. Ducasa GM, Mitrofanova A, Fornoni A (2019) Crosstalk between lipids and mitochondria in diabetic kidney disease. *Curr Diab Rep* 19(12): 144.
19. Vallon V, Scott CT (2012) Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney. *Annu Rev Physiol* 74: 351–375.
20. Rocco MV, Chen Y, Goldfarb S, Ziyadeh FN (1992) Elevated glucose stimulates TGF-beta gene expression and bioactivity in proximal tubule. *Kidney Int* 41(1): 107–114.
21. Chang AS, Hathaway CK, Smithies O, Kakoki M (2016) Transforming growth factor-beta1 and diabetic nephropathy. *Am J Physiol Renal Physiol* 310(8): 689–696.
22. Kanikarla-Marie P, Jain SK (2016) Hyperketonemia and ketosis increase the risk of complications in type 1 diabetes. *Free Radic Biol Med* 95: 268–277.
23. Kanikarla-Marie P, Jain SK (2015) Hyperketonemia (acetoacetate) upregulates NADPH oxidase 4 and elevates oxidative stress, ICAM-1, and monocyte adhesivity in endothelial cells. *Cell Physiol Biochem* 35(1): 364–373.



This work is licensed under Creative Commons Attribution 4.0 License  
DOI: [10.19080/JETR.2022.07.555703](https://doi.org/10.19080/JETR.2022.07.555703)

**Your next submission with Juniper Publishers  
will reach you the below assets**

- Quality Editorial service
- Swift Peer Review
- Reprints availability
- E-prints Service
- Manuscript Podcast for convenient understanding
- Global attainment for your research
- Manuscript accessibility in different formats  
( Pdf, E-pub, Full Text, Audio)
- Unceasing customer service

**Track the below URL for one-step submission**  
<https://juniperpublishers.com/online-submission.php>